Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 115

1.

Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs.

Zaidan SM, Leyre L, Bunet R, Larouche-Anctil E, Turcotte I, Sylla M, Chamberland A, Chartrand-Lefebvre C, Ancuta P, Routy JP, Baril JG, Trottier B, MacPherson P, Trottier S, Harris M, Walmsley S, Conway B, Wong A, Thomas R, Kaplan RC, Landay AL, Durand M, Chomont N, Tremblay CL, El-Far M; Canadian HIV and Aging Cohort Study.

J Acquir Immune Defic Syndr. 2019 Dec 15;82(5):503-513. doi: 10.1097/QAI.0000000000002185.

PMID:
31714430
2.

Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy.

Lee E, Bacchetti P, Milush J, Shao W, Boritz E, Douek D, Fromentin R, Liegler T, Hoh R, Deeks SG, Hecht FM, Chomont N, Palmer S.

Front Microbiol. 2019 Sep 26;10:2214. doi: 10.3389/fmicb.2019.02214. eCollection 2019.

3.

Infrequent HIV infection of circulating monocytes during antiretroviral therapy.

Massanella M, Bakeman W, Sithinamsuwan P, Fletcher JLK, Chomchey N, Tipsuk S, Chalermchai T, Routy JP, Ananworanich J, Valcour VG, Chomont N; SEARCH 011 Study Group.

J Virol. 2019 Oct 9. pii: JVI.01174-19. doi: 10.1128/JVI.01174-19. [Epub ahead of print]

PMID:
31597764
4.

Differentiation to an effector memory phenotype potentiates HIV-l latency reversal in CD4+ T cells.

Kulpa DA, Talla A, Brehm JH, Ribeiro SP, Yuan S, Bebin-Blackwell AG, Miller M, Barnard R, Deeks SG, Hazuda D, Chomont N, Sékaly RP.

J Virol. 2019 Oct 2. pii: JVI.00969-19. doi: 10.1128/JVI.00969-19. [Epub ahead of print]

5.

Viral Blips after Treatment Initiation during Acute HIV Infection.

Crowell TA, Pinyakorn S, Sacdalan C, Kroon E, Colby DJ, Puttamaswin S, Ubolyam S, Trichavaroj R, Butterworth O, Turk E, McCullough C, Chomont N, de Souza M, Robb ML, Phanuphak N, Ananworanich J; RV254/SEARCH010 Study Group.

Clin Infect Dis. 2019 Sep 24. pii: ciz936. doi: 10.1093/cid/ciz936. [Epub ahead of print]

PMID:
31550044
6.

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment.

Salahuddin S, Thomson E, Méziane O, Farnos O, Pagliuzza A, Chomont N, Olivenstein R, Costiniuk C, Jenabian MA.

J Vis Exp. 2019 Jun 23;(148). doi: 10.3791/59427.

PMID:
31282892
7.

HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy.

Miller RL, Ponte R, Jones BR, Kinloch NN, Omondi FH, Jenabian MA, Dupuy FP, Fromentin R, Brassard P, Mehraj V, Chomont N, Poon AFY, Joy JB, Brumme ZL, Routy JP; ORCHID Study Group.

J Virol. 2019 Aug 13;93(17). pii: e00755-19. doi: 10.1128/JVI.00755-19. Print 2019 Sep 1.

PMID:
31189714
8.

Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol.

Routy JP, Isnard S, Mehraj V, Ostrowski M, Chomont N, Ancuta P, Ponte R, Planas D, Dupuy FP, Angel JB; Lilac Study Group.

BMJ Open. 2019 Apr 20;9(4):e028444. doi: 10.1136/bmjopen-2018-028444.

9.

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group.

Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15.

PMID:
31000477
10.

Clinical correlates of HIV-1 DNA and inducible HIV-1 RNA reservoirs in peripheral blood in children with perinatally acquired HIV-1 infection with sustained virologic suppression for at least 5 years.

Bitnun A, Ransy DG, Brophy J, Kakkar F, Hawkes M, Samson L, Annabi B, Pagliuzza A, Morand JA, Sauve L, Chomont N, Lavoie S, Kim J, Sandstrom P, Wender P, Lee T, Singer J, Read SE, Soudeyns H; EPIC Research Group.

Clin Infect Dis. 2019 Mar 28. pii: ciz251. doi: 10.1093/cid/ciz251. [Epub ahead of print]

PMID:
30919879
11.

Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy.

Takata H, Kessing C, Sy A, Lima N, Sciumbata J, Mori L, Jones RB, Chomont N, Michael NL, Valente S, Trautmann L.

J Virol. 2019 May 15;93(11). pii: e02248-18. doi: 10.1128/JVI.02248-18. Print 2019 Jun 1.

PMID:
30918072
12.

Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection.

Pardons M, Baxter AE, Massanella M, Pagliuzza A, Fromentin R, Dufour C, Leyre L, Routy JP, Kaufmann DE, Chomont N.

PLoS Pathog. 2019 Feb 27;15(2):e1007619. doi: 10.1371/journal.ppat.1007619. eCollection 2019 Feb.

13.

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals.

Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sékaly RP, Chomont N.

Nat Commun. 2019 Feb 18;10(1):814. doi: 10.1038/s41467-019-08798-7.

14.

Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation.

Costiniuk CT, Saneei Z, Routy JP, Margolese S, Mandarino E, Singer J, Lebouché B, Cox J, Szabo J, Brouillette MJ, Klein MB, Chomont N, Jenabian MA.

BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.

15.

Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection.

Valle-Casuso JC, Angin M, Volant S, Passaes C, Monceaux V, Mikhailova A, Bourdic K, Avettand-Fenoel V, Boufassa F, Sitbon M, Lambotte O, Thoulouze MI, Müller-Trutwin M, Chomont N, Sáez-Cirión A.

Cell Metab. 2019 Mar 5;29(3):611-626.e5. doi: 10.1016/j.cmet.2018.11.015. Epub 2018 Dec 20.

PMID:
30581119
16.

Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation.

Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A, Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M, Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG.

J Infect Dis. 2019 Mar 15;219(7):1084-1094. doi: 10.1093/infdis/jiy617.

PMID:
30371873
17.

Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals.

Uzzan M, Tokuyama M, Rosenstein AK, Tomescu C, SahBandar IN, Ko HM, Leyre L, Chokola A, Kaplan-Lewis E, Rodriguez G, Seki A, Corley MJ, Aberg J, La Porte A, Park EY, Ueno H, Oikonomou I, Doron I, Iliev ID, Chen BK, Lui J, Schacker TW, Furtado GC, Lira SA, Colombel JF, Horowitz A, Lim JK, Chomont N, Rahman AH, Montaner LJ, Ndhlovu LC, Mehandru S.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaau4711. doi: 10.1126/scitranslmed.aau4711.

18.

HIV persistence in mucosal CD4+ T cells within the lungs of adults receiving long-term suppressive antiretroviral therapy.

Costiniuk CT, Salahuddin S, Farnos O, Olivenstein R, Pagliuzza A, Orlova M, Schurr E, De Castro C, Bourbeau J, Routy JP, Ancuta P, Chomont N, Jenabian MA.

AIDS. 2018 Oct 23;32(16):2279-2289. doi: 10.1097/QAD.0000000000001962.

19.

Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir.

Das B, Dobrowolski C, Luttge B, Valadkhan S, Chomont N, Johnston R, Bacchetti P, Hoh R, Gandhi M, Deeks SG, Scully E, Karn J.

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7795-E7804. doi: 10.1073/pnas.1803468115. Epub 2018 Jul 30.

20.

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.

Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, Rolland M, Takata H, Buranapraditkun S, Intasan J, Chomchey N, Muir R, Haddad EK, Tovanabutra S, Ubolyam S, Bolton DL, Fullmer BA, Gorelick RJ, Fox L, Crowell TA, Trichavaroj R, O'Connell R, Chomont N, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV411 study group.

Nat Med. 2018 Jul;24(7):923-926. doi: 10.1038/s41591-018-0026-6. Epub 2018 Jun 11.

Supplemental Content

Loading ...
Support Center